VEGF165 Therapy Exacerbates Secondary Damage Following Spinal Cord Injury |
| |
Authors: | Richard L. Benton Scott R. Whittemore |
| |
Affiliation: | (1) The Kentucky Spinal Cord Injury Research Center (KSCIRC), University of Louisville School of Medicine, Louisville, Kentucky;(2) The Department of Neurological Surgery, University of Louisville School of Medicine, Louisville, Kentucky;(3) The Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, Kentucky |
| |
Abstract: | Vascular endothelial growth factor (VEGF) demonstrates potent and well-characterized effects on endothelial cytoprotection and angiogenesis. In an attempt to preserve spinal microvasculature and prolong the endogenous neovascular response observed transiently following experimental spinal cord injury (SCI), exogenous recombinant human VEGF (rhVEGF165) was injected into the injured rat spinal cord. Adult female Fischer 344 rats were subjected to moderate SCI (12.5 g-cm) using the NYU impactor. At 72 h after injury, animals were randomly assigned to three experimental groups receiving no microinjection or injection of saline or saline containing 2 g of rhVEGF165. Acutely, VEGF injection resulted in significant microvascular permeability and infiltration of leukocytes into spinal cord parenchyma. 6 weeks postinjection, no significant differences were observed in most measures of microvascular architecture following VEGF treatment, but analysis of histopathology in spinal cord tissue revealed profound exacerbation of lesion volume. These results support the idea that intraparenchymal application of the proangiogenic factor VEGF may exacerbate SCI, likely through its effect on vessel permeability. |
| |
Keywords: | VEGF spinal cord injury vascular permeability inflammation |
本文献已被 PubMed SpringerLink 等数据库收录! |
|